Pfizer and Sun settle Bosulif dispute
06-11-2019
Pavel Kapysh / Shutterstock.com
A subsidiary of Pfizer, Hospira, infringed one of Amgen’s patents and must pay damages of $70 million, the US Court of Appeal for the Federal Circuit has affirmed.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Pfizer, Hospira, US Court of Appeal for the Federal Circuit, US District Court for the District of Delaware, biologic, patent infringement
